Comparing bivalent and quadrivalent HPV vaccines

BMJ (Online)

Volumn 343, Issue 7825, 2011, Pages

  Verheijen, René H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPILLOMATOSIS; PRIORITY JOURNAL; UNITED KINGDOM; UTERINE CERVIX CANCER; CONDYLOMA ACUMINATUM; ECONOMICS; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; MALE; NOTE; PAPILLOMAVIRUS INFECTION;

CONDYLOMATA ACUMINATA; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84858999136     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5720     Document Type: Editorial

References (9)

1. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
2. Kim JJ. Human papillomavirus vaccination in the UK is projected to be beneficial and cost effective. BMJ 2008;337:a842.
3. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:d5775.
4. Department of Health. Annual HPV vaccine coverage in England in 2009/2010. 2011. www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/ DH-123795.
5. Oomen P, Zonnenberg I, De Hoogh P. Opkomst HPV-vaccinaties per 15 juli 2011, geboortecohorten 1997 en 1998. RIVM, 2011. www.rivm.nl/cib/binaries/ Opkomst%20HPVvaccinaties% 20per%2015%20juli%202011%20geboortecohorten%201997%20en% 201998, %20de%20toelichting-tcm92-73203.pdf.
6. Medicines and Healthcare Products Regulatory Agency. Suspected adverse reaction analysis human papillomavirus (HPV) vaccine (brand unspecified). 2010. www.mhra.gov. uk/home/groups/pl-p/documents/websiteresources/con028376.pdf.
7. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;10:705-19.
8. Frazer IH, Leggatt GR, Mattarollo R. Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 2011;29:11-38.
9. Capri S, Gasparini R, Panatto D, Demarteau N. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles. Gynecol Oncol 2011;121:514-21.